Monday , June 18 2018

From the Editor

June, 2018

  • 16 June

    June 16, 2018

    On June 4th the 2018 Apple WWDC (World Wide Developers Conference) took place. This is the meeting where Apple shows us the future for all their products. New hardware, software and apps are introduced by both Apple and developers. There were a couple of interesting apps that were shown that …

    Read More »

Latest Articles

June, 2018

Test Your Knowledge

Clinical Case Vignette: Macronutrients

Mr. Carlson is a man, 52-years of age. He is Caucasian and works as a grocery store manager. His labs show that they were significant for elevated random plasma glucose 166 mg/dL, A1C 7.6% and elevated lipids (TG=175 mg/dL, LDL 148 mg/dL, HDL 38 mg/dL, total cholesterol 221 mg/dL). His physical exam is notable for central abdominal obesity (waist circumference 42”), BP 147/91, HR 72, RR 18, BMI 36 kg/m2, but otherwise normal. He is started on metformin and a dietitian is recommended. The dietitian discusses with him the benefits of medical nutrition therapy on weight, glycemic control, blood pressure, lipid profile, and overall wellbeing. Which following statement regarding macronutrients is true?

Correct

Answer: D. Saturated fat should be <7% of total calories

Educational Critique: Saturated fat should be <7% of the total daily calories. Dietary modifications and the composition of carbohydrates/fats/protein should be adjusted to meet the needs and preferences of the individual patients. Carbohydrate monitoring is still a key component for glycemic control. It can occur in the form of carbohydrate counting, estimation based on experience, or educated food choices. Reduced trans fat intake results in a lower LDL and increased HDL.  — American Dietitians Association

Incorrect

More Articles

June, 2018

  • 16 June

    Cost Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes

    Data from DIAMOND trial to help determine if CGM helps those with consistently high glucose.

    Read More »
  • 16 June

    GLP-1, SGLT-2 Combo

    Have you recommended to any patients the drug treatment of using a GLP-1 receptor agonist and a SGLT-2 inhibitor combination? Follow the link to share your opinion.

    Read More »
  • 12 June

    Once A Pump, Always a Pump? Wrong Again!

    (This is a follow-up to the patient who was under the impression he would always need an insulin pump.) It was a "rocky" start at first. The patient had some early morning highs and some unexpected lows, but likes being off the pump. He wears his Dexcom, which he plans to continue with. This has been extremely helpful with alarms during the adjustments to his long-acting and rapid-acting insulins. The endocrinologist knew the patient was extremely sensitive to insulin, so his rapid-acting insulin has gone from using 1-unit increments to 0.5-unit increments instead and is doing well. At this time, the patient wants to stay off the pump, continue with MDI and the sensor. We're still making minor changes, but getting close to goal.

    Read More »
  • 12 June

    Yehuda Handelsman 2018 Complete Interview

    Yehuda Handelsman, MD, FACP, FNLA, MACE is an endocrinologist in private practice and Medical Director & Principal Investigator of the Metabolic Institute of America. He is a nationally and internationally recognized authority on Diabetes, Lipids, Obesity, HTN and the prevention of cardiovascular disease.

    Read More »
  • 12 June

    Future Use of Technology in Outpatient Care Part 2

    In this week's Homerun Slides, the natural history and progressive behavior of type 2 diabetes.

    Read More »
  • 12 June

    International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #129: Beta-Cell Mass and Function in Human Type 2 Diabetes Part 5

    Loss of beta-cell functional identity: The dominance of beta-cell functional impairment in T2DM implies that beta-cells have lost, at least in part, their normal insulin secretory phenotype. The associated molecular features have been discussed in a number of insightful reviews and research articles, and the role of genetic, epigenetic, transcriptomic and proteomic changes has been described extensively. At the cellular level, beta-cell insulin degranulation and the recently hypothesized beta-cell dedifferentiation phenomenon could play key roles. Insulin granules can be easily identified by electron microscopy on the basis of their typical morphology, characterized by a dense core and a more or less clearly visible halo. In addition, secretory granules can be subdivided into mature and immature, based on distinct ultrastructural, biochemical, and functional, with a relative ratio of 6 to 10 in normal human beta-cells.

    Read More »
  • 12 June

    Yehuda Handelsman 2018 Full Interview

    In this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about his presentation on the contemporary approach to the management of diabetes as a cardiovascular disease.

    Read More »
  • 12 June

    Yehuda Handelsman 2018 Transcript

    In this exclusive interview transcript, Dr. Handelsman discusses the relationship between diabetes and cardiovascular disease, and the impact new diabetes drugs are having on management of both conditions.

    Read More »
  • 12 June

    Yehuda Handelsman Part 1, Introduction & Contemporary Approach to Diabetes

    In part 1 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about his work as an endocrinologist, and about why diabetes is a cardiovascular disease.

    Read More »
  • 12 June

    Yehuda Handelsman Part 2, Changing Diabetes Guidelines

    In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about changing diabetes guidelines and what we've learned through studies of new diabetes drugs.

    Read More »